Proactive Investors - Run By Investors For Investors

Shield Therapeutics' Feraccru drug 'a potential game-changer'

Analyst Riccardo Lowi discusses Shield Therapeutics PLC’s (LON:STX) lead asset Feraccru - a novel and highly differentiated iron formulation, for oral administration, indicated for the treatment of iron deficiency.

 
View full STX profile View Profile

Shield Therapeutics PLC Timeline

Related Videos

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use